Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable
Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.
How this was made

The 30-second read
Why it matters
Guidance raise and positive EBITDA signal operational momentum, but Medicare payment structure remains a risk.
Market read
Earnings call provides fresh guidance that could move ADPT and influence the broader precision‑medicine sector.
What to watch
Potential headwinds from CMS draft rate errors and limited Medicare bundled payments could curb profitability.
Background
Adaptive Biotechnologies discussed Q3 performance and future growth levers for its ClonoSeq platform.
Ticker impact
Q3 results reported $83.9M revenue and raised full-year MRD revenue guidance to $276M-$286M.
potential upside as investors price in higher MRD revenue outlook
The raised guidance exceeds prior expectations and reflects double‑digit growth, likely supporting a price rally.
Market effects
Higher MRD revenue guidance may boost sentiment in the immunosequencing and precision oncology sector.
Positive impact on US biotech equities, especially small‑cap innovators.
Limited to niche biotech space; no broad market effect.
Counterpoint
Guidance may be overly optimistic given Medicare ASP pressure and uncertain CMS rate finalization.
Key entities
- companyAdaptive Biotechnologies
US‑listed biotech firm (ticker ADPT) focusing on immunosequencing.
- executiveChad Robins
CEO of Adaptive Biotechnologies.
- executiveKyle Piskel
CFO of Adaptive Biotechnologies.


